S&P 500   3,120.18 (-0.06%)
DOW   27,934.02 (-0.36%)
QQQ   203.37 (+0.15%)
AAPL   266.29 (-0.30%)
FB   199.32 (+0.97%)
MSFT   150.39 (+0.03%)
GOOGL   1,312.59 (-0.55%)
AMZN   1,752.79 (+0.01%)
CGC   15.32 (+7.74%)
NVDA   207.99 (-2.02%)
MU   46.58 (-2.59%)
BABA   185.25 (+0.35%)
GE   11.50 (+0.52%)
TSLA   359.52 (+2.72%)
T   38.00 (-3.80%)
AMD   41.29 (+3.54%)
ACB   2.34 (+2.63%)
F   8.90 (-0.56%)
PRI   131.64 (+0.41%)
NFLX   302.60 (+0.01%)
BAC   32.94 (-0.06%)
GILD   65.00 (+1.10%)
DIS   148.38 (+0.49%)
S&P 500   3,120.18 (-0.06%)
DOW   27,934.02 (-0.36%)
QQQ   203.37 (+0.15%)
AAPL   266.29 (-0.30%)
FB   199.32 (+0.97%)
MSFT   150.39 (+0.03%)
GOOGL   1,312.59 (-0.55%)
AMZN   1,752.79 (+0.01%)
CGC   15.32 (+7.74%)
NVDA   207.99 (-2.02%)
MU   46.58 (-2.59%)
BABA   185.25 (+0.35%)
GE   11.50 (+0.52%)
TSLA   359.52 (+2.72%)
T   38.00 (-3.80%)
AMD   41.29 (+3.54%)
ACB   2.34 (+2.63%)
F   8.90 (-0.56%)
PRI   131.64 (+0.41%)
NFLX   302.60 (+0.01%)
BAC   32.94 (-0.06%)
GILD   65.00 (+1.10%)
DIS   148.38 (+0.49%)
S&P 500   3,120.18 (-0.06%)
DOW   27,934.02 (-0.36%)
QQQ   203.37 (+0.15%)
AAPL   266.29 (-0.30%)
FB   199.32 (+0.97%)
MSFT   150.39 (+0.03%)
GOOGL   1,312.59 (-0.55%)
AMZN   1,752.79 (+0.01%)
CGC   15.32 (+7.74%)
NVDA   207.99 (-2.02%)
MU   46.58 (-2.59%)
BABA   185.25 (+0.35%)
GE   11.50 (+0.52%)
TSLA   359.52 (+2.72%)
T   38.00 (-3.80%)
AMD   41.29 (+3.54%)
ACB   2.34 (+2.63%)
F   8.90 (-0.56%)
PRI   131.64 (+0.41%)
NFLX   302.60 (+0.01%)
BAC   32.94 (-0.06%)
GILD   65.00 (+1.10%)
DIS   148.38 (+0.49%)
S&P 500   3,120.18 (-0.06%)
DOW   27,934.02 (-0.36%)
QQQ   203.37 (+0.15%)
AAPL   266.29 (-0.30%)
FB   199.32 (+0.97%)
MSFT   150.39 (+0.03%)
GOOGL   1,312.59 (-0.55%)
AMZN   1,752.79 (+0.01%)
CGC   15.32 (+7.74%)
NVDA   207.99 (-2.02%)
MU   46.58 (-2.59%)
BABA   185.25 (+0.35%)
GE   11.50 (+0.52%)
TSLA   359.52 (+2.72%)
T   38.00 (-3.80%)
AMD   41.29 (+3.54%)
ACB   2.34 (+2.63%)
F   8.90 (-0.56%)
PRI   131.64 (+0.41%)
NFLX   302.60 (+0.01%)
BAC   32.94 (-0.06%)
GILD   65.00 (+1.10%)
DIS   148.38 (+0.49%)
Log in

Axcella Health Stock Price, Forecast & Analysis (NASDAQ:AXLA)

$3.38
+0.30 (+9.74 %)
(As of 11/19/2019 04:00 PM ET)
Today's Range
$2.76
Now: $3.38
$3.94
50-Day Range
$3.08
MA: $5.05
$6.93
52-Week Range
$2.76
Now: $3.38
$15.99
Volume120,700 shs
Average Volume31,834 shs
Market Capitalization$78.13 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
There is no company description available for Axcella Health Inc.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AXLA
CUSIPN/A
CIKN/A
Phone857-320-2200

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Net Income$-36,070,000.00

Miscellaneous

EmployeesN/A
Market Cap$78.13 million
Next Earnings Date2/11/2020 (Estimated)
OptionableNot Optionable

Receive AXLA News and Ratings via Email

Sign-up to receive the latest news and ratings for AXLA and its competitors with MarketBeat's FREE daily newsletter.


Axcella Health (NASDAQ:AXLA) Frequently Asked Questions

What is Axcella Health's stock symbol?

Axcella Health trades on the NASDAQ under the ticker symbol "AXLA."

How were Axcella Health's earnings last quarter?

Axcella Health Inc (NASDAQ:AXLA) issued its quarterly earnings data on Tuesday, November, 12th. The company reported ($0.75) EPS for the quarter, missing the consensus estimate of ($0.71) by $0.04. View Axcella Health's Earnings History.

When is Axcella Health's next earnings date?

Axcella Health is scheduled to release their next quarterly earnings announcement on Tuesday, February 11th 2020. View Earnings Estimates for Axcella Health.

What price target have analysts set for AXLA?

4 brokerages have issued 12 month price targets for Axcella Health's shares. Their forecasts range from $11.00 to $25.00. On average, they anticipate Axcella Health's share price to reach $19.00 in the next year. This suggests a possible upside of 462.1% from the stock's current price. View Analyst Price Targets for Axcella Health.

What is the consensus analysts' recommendation for Axcella Health?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Axcella Health in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Axcella Health.

Has Axcella Health been receiving favorable news coverage?

News coverage about AXLA stock has trended negative on Tuesday, InfoTrie reports. InfoTrie identifies positive and negative media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Axcella Health earned a news sentiment score of -2.2 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the next few days. View News Stories for Axcella Health.

Are investors shorting Axcella Health?

Axcella Health saw a increase in short interest in October. As of October 31st, there was short interest totalling 41,700 shares, an increase of 8.9% from the September 30th total of 38,300 shares. Based on an average trading volume of 9,700 shares, the days-to-cover ratio is presently 4.3 days. Currently, 0.5% of the company's shares are sold short. View Axcella Health's Current Options Chain.

Who are some of Axcella Health's key competitors?

What other stocks do shareholders of Axcella Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Axcella Health investors own include Triton International (TRTN), Main Street Capital (MAIN), Achillion Pharmaceuticals (ACHN), Adobe (ADBE), Blackline (BL), Coda Octopus Group (CODA), Exelixis (EXEL), Stamps.com (STMP), Xilinx (XLNX) and Delek US (DK).

When did Axcella Health IPO?

(AXLA) raised $76 million in an IPO on Thursday, May 9th 2019. The company issued 3,600,000 shares at a price of $20.00-$22.00 per share. Goldman Sachs, J.P. Morgan and SVB Leerink served as the underwriters for the IPO.

When did Axcella Health's lock-up period expire?

Axcella Health's lock-up period expired on Tuesday, November 5th. Axcella Health had issued 3,571,428 shares in its initial public offering on May 9th. The total size of the offering was $71,428,560 based on an initial share price of $20.00. Shares of the company owned by major shareholders and company insiders are now eligible to be traded as a result of the end of the lock-up period.

How do I buy shares of Axcella Health?

Shares of AXLA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Axcella Health's stock price today?

One share of AXLA stock can currently be purchased for approximately $3.38.

How big of a company is Axcella Health?

Axcella Health has a market capitalization of $78.13 million. View Additional Information About Axcella Health.

What is Axcella Health's official website?

The official website for Axcella Health is http://www.axcellahealth.com/.

How can I contact Axcella Health?

Axcella Health's mailing address is 840 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The company can be reached via phone at 857-320-2200.


MarketBeat Community Rating for Axcella Health (NASDAQ AXLA)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  28 (Vote Outperform)
Underperform Votes:  33 (Vote Underperform)
Total Votes:  61
MarketBeat's community ratings are surveys of what our community members think about Axcella Health and other stocks. Vote "Outperform" if you believe AXLA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AXLA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/19/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel